From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic
- Apr 27
- 1 min read
CEO Elias Paptheodorou walks us through the data and descirbes how this has already been tested (for safety) in five cancer patients who had small portions of their liver resected. The next step is to test it in patients with major resections, and also a randomized phase 2a, both of which the company already has the cash to fund.
.png){kind=logo}